GNI Group Ltd.

Equities

2160

JP3386370005

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 16/07/2024 BST			5-day change	1st Jan Change
2,558 ^JPY	+0.83%		+3.73%	-9.61%

07-01	GNI Group Ltd. Announces GYRE Pharmaceuticals Receives Approval from the National Medical Products Administration for Avatrombopag Maleate Tablets	CI
05-31	Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	MT

GNI Group Ltd. Announces GYRE Pharmaceuticals Receives Approval from the National Medical Products Administration for Avatrombopag Maleate Tablets

July 01, 2024 at 10:30 am

GNI Group Ltd. announced that the market application of "Avatrombopag Maleate Tablets (20mg)", the treatment for thrombocytopenia associated with chronic liver disease (CLD), which the Company's major subsidiary GYRE Pharmaceuticals has been developing in China, received approval from the National Medical Products Administration on June 25, 2024. This product will be the third product in the Company Group's sales lineup, following ETUARY and Nintedanib. In addition, it is a generic drug for rare diseases.

the Group will continue to innovate and expand its R&D pipeline to provide more options to patients with rare diseases in both new and generic drugs.

Latest news about GNI Group Ltd.

GNI Group Ltd. Announces GYRE Pharmaceuticals Receives Approval from the National Medical Products Administration for Avatrombopag Maleate Tablets	07-01	CI
Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	05-31	MT
Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy	03-19	MT
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024	02-14	CI
Jefferies Upgrades GNI to Buy From Hold, Adjusts Price Target to 3,000 Yen From 1,500 Yen	11-17	MT
GNI Group Revises Fiscal 2023 Forecast Upwards after Subsidiaries Show Better-than-Expected Sales, Foreign Exchange Rates	11-06	MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	11-06	CI
GNI Group Ltd. Announces New Management Structure	28/09/23	CI
GNI Group Ltd. Announces New Management Structure	28/09/23	CI
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business	20/09/23	MT
Wall Street Set to Open Marginally Lower as Fed Kicks Off September Policy Meeting	19/09/23	MT
Equity Futures Trend Higher as Investors Expect No Rate Hike From Fed	19/09/23	MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms	19/09/23	DJ
Elutia Sells Orthobiologics Business Unit For Up to $35 Million	18/09/23	MT
GNI Group issues 1,350 Stock Acquisition Rights	13/09/23	MT
GNI Group to Issue 1,350 Stock Options; Shares Up 3%	29/08/23	MT
GNI Subsidiary Cullgen Closes Series C Funding	23/08/23	MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2023	03/08/23	CI
GNI Group Invests in Shanghai JIUCE Medical Device Technology via Subsidiary	02/08/23	MT
GNI Completes Investment in Shanghai JIUCE for China Expansion	02/08/23	MT
Gni Group Ltd. Announces Notice of Executive Officer Appointment	03/07/23	CI
Jefferies Downgrades GNI Group to Hold From Buy, Adjusts Price Target to 1,500 Yen From 1,300 Yen	19/06/23	MT
Japan Shares Rise as Central Bank Maintains Policy Status Quo; Toyota to Receive 120 Billion Yen of Subsidies	16/06/23	MT
GNI Group Unit, Astellas Pharma Partner to Discover Innovative Protein Degraders	16/06/23	MT
GNI Group Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI

Chart GNI Group Ltd.

Duration

Period

More charts

Company Profile

GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for GNI Group Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,558 JPY

Average target price

4,100 JPY

Spread / Average Target

+60.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GNI GROUP LTD.	-9.61%	803M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research